Literature DB >> 22905058

Subclinical haemorrhagic tendency exists in patients with β-thalassaemia major in early childhood.

Abhishek Maiti1, Amartya Chakraborti, Puranjoy Chakraborty, Sanjay Mishra.   

Abstract

BACKGROUND: Alterations of coagulation profile have been reported in patients with β-thalassaemia major (β-TM).
METHOD: To investigate this in the paediatric population, we studied haemostatic parameters in pre-transfusion blood samples from 50 non-splenectomised transfusion-dependent children with β-TM (mean age 6±2.5 years) and in blood from 25 healthy controls.
RESULTS: Laboratory evaluation showed thrombocytopenia in 40%, prolongation of prothrombin time (PT) in 12% and prolongation of activated partial thromboplastin time (APTT) in 6% of the patients. Mean values for PT, APTT and platelet count (PC) were all raised in the patient population compared with the controls. The alteration of coagulation status was significant for PT (p value <0.005) and APTT (p value <0.0001). However, the change for PC was not significant (p value <0.05). No significant liner correlation could be identified between PT, APTT, PC of the patients and interval between transfusions (in days) or days since last transfusion.
CONCLUSION: The findings from this study suggest that a subclinical haemorrhagic tendency exists in patients with β-TM at a very early age. The intrinsic pathway appears to be more affected than the extrinsic pathway.

Entities:  

Keywords:  Activated Partial Thromboplastin Time; Coagulation; Haemorrhage; Prothrombin Time; Thalassaemia Major

Year:  2012        PMID: 22905058      PMCID: PMC3413934          DOI: 10.4066/AMJ.20121076

Source DB:  PubMed          Journal:  Australas Med J        ISSN: 1836-1935


  12 in total

1.  The spectrum of beta-thalassaemia mutations on the Indian subcontinent: the basis for prenatal diagnosis.

Authors:  N Y Varawalla; J M Old; R Sarkar; R Venkatesan; D J Weatherall
Journal:  Br J Haematol       Date:  1991-06       Impact factor: 6.998

Review 2.  The hypercoagulable state in thalassemia.

Authors:  Amiram Eldor; Eliezer A Rachmilewitz
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

3.  Thromboembolic events in beta thalassemia major: an Italian multicenter study.

Authors:  C Borgna Pignatti; V Carnelli; V Caruso; F Dore; D De Mattia; A Di Palma; F Di Gregorio; M A Romeo; R Longhi; A Mangiagli; C Melevendi; G Pizzarelli; S Musumeci
Journal:  Acta Haematol       Date:  1998       Impact factor: 2.195

4.  Screening coagulation tests and clotting factors in homozygous beta-thalassemia.

Authors:  L Caocci; M Alberti; P Burrai; R Corda
Journal:  Acta Haematol       Date:  1978       Impact factor: 2.195

5.  Hematuria in patients with Beta-thalassemia major.

Authors:  Mohammad Hossein Fallahzadeh; Mohammad Kazem Fallahzadeh; Mehdi Shahriari; Shervin Rastegar; Ali Derakhshan; Mohammad Amin Fallahzadeh
Journal:  Iran J Kidney Dis       Date:  2010-04       Impact factor: 0.892

6.  Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia.

Authors:  M D Cappellini; L Robbiolo; B M Bottasso; R Coppola; G Fiorelli; A P Mannucci
Journal:  Br J Haematol       Date:  2000-11       Impact factor: 6.998

7.  A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood.

Authors:  A Eldor; R Durst; E Hy-Am; A Goldfarb; S Gillis; E A Rachmilewitz; A Abramov; J MacLouf; Y C Godefray; E De Raucourt; M C Guillin
Journal:  Br J Haematol       Date:  1999-12       Impact factor: 6.998

8.  Protein C and antithrombin III in polytransfused thalassemic patients.

Authors:  S Musumeci; S Leonardi; R Di Dio; A Fischer; G Di Costa
Journal:  Acta Haematol       Date:  1987       Impact factor: 2.195

9.  Hemorrhagic tendency in beta-thalassemia major.

Authors:  A Eldor
Journal:  Isr J Med Sci       Date:  1978-11

10.  Myocardial infarction in a patient with beta-thalassemia major: first report.

Authors:  Zvi G Fridlender; Deborah Rund
Journal:  Am J Hematol       Date:  2004-01       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.